Bergen 4-Day Treatment Delivers Faster and Deeper OCD Symptom Relief Than iCBT
Obsessive-compulsive disorder remains a difficult condition to treat at scale because the most effective therapies are also among the most resource-intensive. In a single-center randomized clinical trial, the Bergen 4-day treatment (B4DT), a concentrated exposure-based intervention, produced larger reductions in OCD severity than an 8-week unguided internet-based cognitive behavioral therapy program, with benefits that persisted through 3 months of follow-up.
The contrast was sharp at every measured point after treatment began. Adults assigned to B4DT improved more than those assigned to iCBT on the Yale-Brown Obsessive Compulsive Scale, the field’s standard clinician-rated measure of symptom burden, and the gap remained clinically meaningful after the active treatment phase ended.
Trial Design Focused on Symptom Severity, Function, and Durability
The study enrolled adults aged 18 to 72 years with OCD between May 8, 2024, and August 8, 2025, and followed them for 3 months. Of 253 people screened, 119 entered the trial after 53 were deemed ineligible and 81 declined participation. Randomization assigned 60 participants to B4DT and 59 to iCBT, with masked evaluators assessing outcomes at baseline, 6 weeks, 8 weeks, and 3 months.
Exclusion criteria removed several groups for whom the trial’s intervention comparison could have been confounded or unsafe, including people with schizophrenia, bipolar disorder, acute suicidality, substance dependence, or recent psychopharmacological changes. The resulting sample was relatively young, with a mean age of 33.5 years, and two-thirds were women. Those characteristics matter because OCD often emerges early in life and can persist for years before patients reach specialized care.
Exposure-based treatment targets the compulsions and avoidance patterns that keep OCD alive. By repeatedly confronting feared triggers while preventing ritualized responses, patients can learn that distress falls without the need for compulsive relief. A compressed model such as B4DT concentrates that learning into a narrow time window, which may strengthen engagement and reduce the dropout burden that often weakens longer programs.
Large Symptom Differences Emerged by Posttreatment
At posttreatment, B4DT outperformed iCBT on the primary endpoint by a wide margin. The adjusted mean difference in Y-BOCS change was -7.9 points with a standard error of 0.9, and the 95% confidence interval ranged from -9.7 to -6.0. The reported Hedges g of -1.6 indicates a large effect size, one that is difficult to dismiss as a minor statistical artifact.
The gap did not disappear during follow-up. At 3 months, the mean difference remained -5.6 points with a standard error of 1.1, the 95% confidence interval ranged from -7.8 to -3.4, and Hedges g was -1.0. In a disorder where patients often cycle through partial responses, residual symptoms, and relapse, persistence of benefit matters as much as the initial drop in score.
B4DT also performed better across the secondary outcomes, which included self-reported OCD severity, dysfunctional cognitions, quality of life, depressive symptoms, experiential avoidance, global functioning, self-esteem, and treatment satisfaction. The broad pattern suggests that symptom relief was not isolated to one rating scale; it extended into the domains that shape daily living and perceived recovery.
Response and Remission Rates Favored the Intensive Model
The clinical endpoint most relevant to patients and clinicians is not merely lower symptom scores but whether treatment moves someone into response or remission. By 3 months, response occurred in 35 of 57 participants receiving B4DT, or 61.4%, compared with 11 of 44 receiving iCBT, or 25.0%. Remission showed a similar separation: 24 of 57 participants in the B4DT group, or 42.1%, versus 6 of 44 in the iCBT group, or 13.6%.
Those numbers point to more than incremental superiority. They suggest that front-loading exposure work, therapist contact, and behavioral rehearsal can push a larger share of patients across thresholds that are meaningful in routine practice. For OCD, where avoidance and ritual repetition can be deeply entrenched, a short burst of intensive treatment may interrupt those habits more decisively than a slower self-directed format.
Unguided internet CBT still has value. It can lower logistical barriers and may extend evidence-based care to settings where specialty therapists are scarce. Yet this trial shows that a low-intensity digital model did not match the outcomes of a tightly structured in-person exposure program when the target was symptom reduction in established OCD.
Access, Intensity, and the Practical Meaning of a Brief Exposure Model
The appeal of B4DT is obvious from a health systems perspective. A four-day intervention with preparatory sessions compresses care into a format that may be easier for patients to complete and easier for clinics to schedule than extended weekly treatment. In OCD, where delays in care often stretch for years, the ability to deliver effective treatment quickly could reduce the duration of suffering and the cumulative disability tied to compulsions, avoidance, and functional impairment.
The biology of exposure therapy helps explain why a short treatment can work so well. Repeated non-ritualized contact with feared stimuli disrupts the reinforcement cycle that teaches the brain to treat obsessional threat as immediate and unavoidable. When patients discover they can tolerate distress without performing compulsions, the fear structure itself can weaken, and symptom control can improve rapidly.
The trial’s design still leaves important boundaries around interpretation. It was single-center, and the comparison involved unguided iCBT rather than a therapist-supported digital program. The follow-up period was limited to 3 months, so the durability of benefit beyond that point remains unknown from these data alone. Even so, the consistency of the primary and secondary outcomes gives the findings real clinical weight.
For clinicians treating OCD, the message is straightforward: an intensive, exposure-based model can outperform a self-directed internet program on both symptom severity and recovery thresholds. The next question is not whether B4DT can work, but how broadly it can be deployed, which patients are best suited to it, and whether its gains hold when implemented outside a specialized research setting.